# Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib

> **NCT01928160** · PHASE2 · WITHDRAWN · sponsor: **Vanderbilt-Ingram Cancer Center**

## Conditions studied

- Recurrent Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer

## Interventions

- **DRUG:** pemetrexed disodium
- **DRUG:** carboplatin
- **DRUG:** cisplatin
- **DRUG:** erlotinib hydrochloride
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01928160
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-06
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** study not accruing
- **Last updated:** 2015-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01928160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01928160, "Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01928160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*